Introduction
Recent studies have demonstrated the involvement of several soluble factors with different functions in the growth and differentiation of antigen-stimulated B cells (1) (2) (3) . Several of these factors have been well characterized and the gene encoding B cell stimulatory factor-I (BSF-1),' which was originally designated B cell growth factor-I (BCGF-I) has been cloned (4, 5) . BSF-l shows synergy with anti-IgM in the proliferation ofresting B cells. BSF-1 is not strictly a growth factor; however, it is responsible for the activation of resting B cells (6) (7) (8) . Therefore, a growth factor for B cells comparable to interleukin 2 (IL-2) for T cells has yet to be identified. Our previous report (9) as well as several other studies (10) (11) (12) (13) (14) showed that activated B cells or transformed B cell lines secreted B cell growth factor(s) that could induce the proliferation of activated, but not resting 1 . Abbreviations used in this paper: anti-s, anti-IgM; BCGF, B cell growth factor; BCDF, B cell differentiation factor; BSF-1, B cell stimulatory factor-i; CLL, chronic lymphocytic leukemia; EBV, Epstein Barr virus; EBNA, Epstein Barr nuclear antigen; FACS, fluorescence activated cell sorter; FCS, fetal calfserum; FITC, fluoroisothiocyanate; y-IFN, gamma interferon; HTLV, human T cell leukemia virus; IL-I, 2 Reagents. Staphylococcus aureus Cowan I (SAC) was obtained from Hoechst Japan, Ltd., (Tokyo). Phytohemagglutinin-P (PHA) was purchased from Difco Laboratories (Detroit, MI). F(ab')2 fragment of goat anti-human IgM (anti-a) was purchased from Cappel Laboratories (Cochranville, PA). Recombinant IL-I (rIL-1) was a gift ofOtsuka Pharmaceutical Co., Ltd. (Tokushima, Japan). Recombinant IL-2 (rIL-2) was provided from Ajinomoto Co., Ltd., Tokyo. 1 U of IL-I or IL-2 was defined as the activity that gave 50% of the maximum proliferative response. B cell differentiation factor (BSF-2) was purified in this laboratory from a human T cell leukemia virus (HTLV)-transformed T cell clone, Na-I, as previously described (16) . 100 pM of purified BCDF gave maximum response in a BCDF assay, in which Ig secretion from EBV-transformed B cell lines or SAC-activated B cells was measured (16) . B-BCGF was prepared from a B cell line, RPMI 1788, as described in a previous report (9) . PHA-conditioned medium from T cells (PHA-T supernatant) was prepared by a method described previously (17 (26) . Freshly separated PBL from K.H. was found to be negative with the anti-EBNA sera, while all three established cell lines from PBL of the patient were found to be positive with the anti-EBNA sera.
Results
Analysis ofsurface phenotypes andIggene configuration ofPBL from the B-CLL patient (K.H.). The surface phenotype of the PBL from K.H. is summarized in Table I . More than 90% of PBL (26,500/mm3) were B cells as judged by BI expression and the percentage of T cells was less than 10% as judged by T3 expression. Two-color FACS analysis, shown in Fig. 1 , A-D, demonstrated that >90% of PBL expressed the B1 antigen, but did not express the Ba antigen (27) . Very few cells expressed the Tac antigen or the Leu 4 antigen. Of note is that the majority ofthe cells strongly expressed both IgM and IgD on their surface, which is unusual in the case of B-CLL. All surface IgM' cells expressed Leu 1, which is a common feature of B-GLL (28) .
In order to study the clonality of the B cells, the rearrangement of Ig genes was examined. The DNA from patient PBL or from human placenta was digested with Hind III or Xba I and the fragments were hybridized with the 3.5-kb JH Hind III/Eco RI probe (Fig. 2, lane 1 and 2 ). The Hind III restriction fragments of patient PBL gave a 6.0-kb (kilobase) band (lane 2), while those of placenta showed an expected 10.9-kb band (lane 1).
The Xba I fragments of patient PBL gave two bands of 6.6 and 6.0-kb, respectively, (lane 2), whereas those of placenta showed the expected 6 with anti-it, SAC, rIL-l, rIL-2, or B cell-derived BCGF (9) , and the proliferative responses were measured. As listed in Table II , rIL-1, rIL-2, rIL-I plus rIL-2, SAC, and BCGF did not induce any significant proliferation of those B cells. Some proliferative response was observed by anti-Ig stimulation and the addition of B-BCGF with anti-M synergistically augmented this proliferation. It is noteworthy that B cells freshly isolated from the patient did not express Ba (Fig. 1 A) , which is expressed on activated B cells at GI phase, but not on resting B cells (27 Growth factor production by leukemic B cells from the B-CLL patient (K.H.). Anti-M stimulation of the leukemic B cells in the absence ofBCGF induced a significant proliferation (Table  II) the supernatant in the presence or absence of suboptimal concentrations of mitogens. The supernatant did not induce any proliferation of nonstimulated or PHA-stimulated T cells (data not shown). In contrast, it induced a significant proliferation of anti-is-stimulated B cells in a dose-dependent fashion, but no response with nonstimulated B cells (Fig. 4) (Fig. 8) . There was no increase in the expression of HLA-DR in B cells cultured with KHB1 supernatant, whereas there was a significant enhancement ofthe HLA-DR expression on resting B cells cultured with anti-iu or PHA-T supernatant as previously reported (9) .
These data indicate that BCGF in KHB1 supernatant delivers a progression signal for proliferation, but not a competence signal responsible for the activation of resting B cells. In order to study whether the established cell lines are able to respond to autologous growth factor, KHB1 cells were cultured with various concentrations of KHB1 supernatant and the proliferative responses were measured (Fig. 9) . There was no augmentation of DNA synthesis in KHB1 cells by the addition of autologous culture supernatant, whereas the same supernatant could induce or augment the proliferation of anti-,i-stimulated B blast cells or that of a B lymphoblastoid cell line, RPMI 1788. Face analysis with FACS also showed that Ba molecules, re expressed only on activated B cells at G1 phase (27) 
